CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
8.69
-0.37 (-4.08%)
At close: Dec 5, 2025, 4:00 PM EST
8.85
+0.16 (1.84%)
After-hours: Dec 5, 2025, 7:26 PM EST
CervoMed Revenue
CervoMed had revenue of $322.57K in the quarter ending September 30, 2025, a decrease of -83.37%. This brings the company's revenue in the last twelve months to $6.16M, down -38.81% year-over-year. In the year 2024, CervoMed had annual revenue of $9.74M with 36.29% growth.
Revenue (ttm)
$6.16M
Revenue Growth
-38.81%
P/S Ratio
12.56
Revenue / Employee
$410,652
Employees
15
Market Cap
80.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
| Dec 31, 2023 | 7.14M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCRVO News
- 1 day ago - CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - GlobeNewsWire
- 4 days ago - CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) - GlobeNewsWire
- 12 days ago - CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 6 weeks ago - CervoMed to Present at the Emerging Growth Conference - GlobeNewsWire
- 2 months ago - CervoMed Drug Cut Dementia Progression Risk By 75% In Trial - Benzinga
- 2 months ago - CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies - GlobeNewsWire
- 2 months ago - CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 2 months ago - CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference - GlobeNewsWire